V-Bio Ventures

V-Bio Ventures

We are a life sciences fund investing throughout Europe in start-up and early-stage companies with high growth potential. Our articles cover investment-related topics in life sciences, including innovation trends, the latest business themes and exciting updates on our portfolio companies.

The million-dollar question: How much do you charge for a lifesaving drug?

The newest generation of ground-breaking gene therapy drugs, Zolgensma and Zynteglo, come with eye-catching price tags of more than a million dollars per treatment. Is the pharma industry recklessly overstepping a line here, or do they fall within current standards of value-based drug pricing? With more of these drugs soon to be rolling out of pharma pipelines, the stakes are rising high for patients, industry, governments, health insurance companies, as well as investors. It all warrants a deeper dive into the case. August 26, 2019 · V-Bio Ventures

Investing in European biotech faced with many challenges

Investing in biotech companies is a capital-intensive and risky business, and it’s no secret that more money and less risk-averse investors are available in the US than in Europe. To keep innovations, companies, and their economic benefits from being transferred to regions outside Europe, many national and international European initiatives are in place. The question remains whether this is sufficient to fundamentally improve Europe’s currently underfunded biotech ecosystem. The biotech investment specialists of V-Bio Ventures take us through Europe’s biotech investment landscape.

March 16, 2017 · V-Bio Ventures